• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Elicera Therapeutics

2.85 SEK

+10.27 %

Less than 1K followers

ELIC

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+10.27 %
-1.39 %
-46.33 %
-44.06 %
-44.06 %
-51.09 %
+2.45 %
-37.48 %
-52.91 %

Elicera Therapeutics AB is a clinical phase cell and gene therapy company that develops the next generation of immuno-oncology treatments. The work is based on high-profile long-standing research conducted by Professor Magnus Essand's research group at Uppsala University and has resulted in the development of four drug candidates, including two CAR T cells and two oncolytic viruses.

Read more
Market cap
189.86M SEK
Turnover
2.03M SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Research
Press releases
3rd party
ShowingAll content types

Revenue and EBIT-%

Revenue K

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
21/8
2026

Interim report Q2'26

27/11
2026

Interim report Q3'26

16/2
2027

Annual report '26

Press release2026-07-02 07:27

BioStock: BioStock publicerar BioVal™-analys av Elicera Therapeutics ELC-301-projekt

Elicera Therapeutics
Press release2026-07-02 07:27

BioStock: BioStock publish BioVal™ analysis of Elicera Therapeutics' ELC-301 programme

Elicera Therapeutics
Regulatory press release2026-06-25 14:01

Kommuniké från årsstämma i Elicera Therapeutics AB (publ) den 25 juni 2026

Elicera Therapeutics

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release2026-06-18 15:22

Elicera Therapeutics Receives Positive Feedback from Swedish MPA on Planned Clinical Study with ELC-401 in Grade IV Glioma

Elicera Therapeutics
Press release2026-06-18 15:22

Elicera Therapeutics får positiv feedback från Läkemedelsverket om planerad klinisk studie med ELC-401 för gliom grad IV

Elicera Therapeutics
Regulatory press release2026-06-08 08:40

Elicera Therapeutics: Eliceras valberedning föreslår Margareth Jorvid som ny styrelseordförande

Elicera Therapeutics
Regulatory press release2026-06-08 08:40

Elicera Therapeutics: Elicera's Nomination Committee Proposes Margareth Jorvid as New Chair of the Board

Elicera Therapeutics
Regulatory press release2026-06-03 17:01

Elicera Therapeutics: Elicera publishes annual report for 2025

Elicera Therapeutics
Regulatory press release2026-06-03 17:01

Elicera Therapeutics: Elicera publicerar årsredovisningen för 2025

Elicera Therapeutics
Regulatory press release2026-06-01 17:46

Elicera Therapeutics: Elicera offentliggör utfall i Företrädesemission

Elicera Therapeutics
Regulatory press release2026-06-01 17:46

Elicera Therapeutics: Elicera announces outcome of the rights issue

Elicera Therapeutics
Press release2026-05-25 09:10

Elicera Therapeutics meddelar att slutrapportering och slutgiltig utbetalning från EIC Accelerator för CARMA-studien har godkänts

Elicera Therapeutics
Press release2026-05-25 09:10

Elicera Therapeutics announces that the final reporting and final payment from the EIC Accelerator for the CARMA study have been approved

Elicera Therapeutics
Regulatory press release2026-05-22 08:01

Kallelse till årsstämma i Elicera Therapeutics AB (publ)

Elicera Therapeutics
Press release2026-05-19 10:10

DNB Carnegie Access: Elicera Therapeutics - Extended company presentation and Q&A

Elicera Therapeutics
Press release2026-05-19 07:42

Elicera Therapeutics publicerar presentation och Q&A

Elicera Therapeutics
Press release2026-05-13 15:57

Elicera Therapeutics CSO tar tillfälligt ledigt för att genomgå medicinsk behandling - Di Yu utses till biträdande CSO

Elicera Therapeutics
Press release2026-05-13 15:57

Elicera Therapeutics' CSO takes temporary leave to undergo medical treatment - Di Yu appointed Acting CSO

Elicera Therapeutics
Press release2026-05-12 16:55

Carlsquare: Analysuppdatering Elicera Therapeutics: Höjer insatserna efter framsteg

Elicera Therapeutics
Regulatory press release2026-05-11 14:16

Elicera Therapeutics: Elicera offentliggör informationsdokument inför företrädesemissionen

Elicera Therapeutics